RxDoctor Payments Data

Daniel Sines, MD

Ophthalmology · Rogers, ARNPI 1508028218

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $66,550 of the $81,074 with a category attached, or 82.1%. Amgen accounts for 98.2% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $22,330, more than ten times the $269 reported in 2019. Among ophthalmology clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$81,074in general payments, 2019–2025

Across 166 payments — averaging $488.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$80K
  • Carl Zeiss Meditec USA, Inc.$293
  • Biotissue Holdings Inc.$237
  • Tarsus Pharmaceuticals, Inc.$174
  • Glaukos Corporation$108
  • Bausch & Lomb Americas Inc.$99
  • plus $577 from 11 others

What the payments were for

  • Consulting fees$5,1006%
  • Speaking & faculty fees$66,55082%
  • Travel & lodging$4,8496%
  • Food & beverage$4,2205%
  • Entertainment$620%
  • Other$2930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$81,074 in reported general payments places this provider in the 95th percentile of 125 ophthalmology providers in Arkansas.

See all ophthalmology providers in Arkansas

Medicare billing

Part B allowed, 2024
$532,273
Medicare patients
821
Services billed
7,268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine45$36,616
XiidraLifitegrast38$35,126
BotoxOnabotulinumtoxina36$27,423
ErythromycinErythromycin Base675$6,141
Doxycycline Hyclate244$4,047
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha227$2,382
Latanoprost103$1,069
Prednisolone Acetate24$608
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen175$572
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat36$480
Brimonidine Tartrate16$203
Cephalexin25$184
Timolol Maleate27$138
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen18$43
Diazepam12$6

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Botox$86$64,03981 claims
Bausch & Lomb Americas Inc.Xiidra$99$35,12638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 125 ophthalmology providers in Arkansas.

Other ophthalmology in Rogers

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →